Cargando…

Anti-VEGF Therapy and the Retina: An Update

Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tah, Vikas, Orlans, Harry O., Hyer, Jonathan, Casswell, Edward, Din, Nizar, Sri Shanmuganathan, Vishnu, Ramskold, Louise, Pasu, Saruban
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568374/ https://www.ncbi.nlm.nih.gov/pubmed/26417453 http://dx.doi.org/10.1155/2015/627674

Ejemplares similares

PIMS (Positioning In Macular hole Surgery) trial – a multicentre interventional comparative randomised controlled clinical trial comparing face-down positioning, with an inactive face-forward position on the outcome of surgery for large macular holes: study protocol for a randomised controlled trial
por: Pasu, Saruban, et al.
Publicado: (2015)

Positioning In Macular hole Surgery (PIMS): statistical analysis plan for a randomised controlled trial
por: Bell, Lauren, et al.
Publicado: (2017)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
por: Corazza, Paolo, et al.
Publicado: (2021)

Giving anti-VEGF injections: an update from Burundi
por: Niyonzima, Jean Claude
Publicado: (2023)

Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina
por: Patrício, Maria I., et al.
Publicado: (2017)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Central and Peripheral Retina Arise through Distinct Developmental Paths
por: Venters, Sara J., et al.
Publicado: (2013)

Facedown Positioning Following Surgery for Large Full-Thickness Macular Hole: A Multicenter Randomized Clinical Trial
por: Pasu, Saruban, et al.
Publicado: (2020)

Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients
por: Filek, Richard, et al.
Publicado: (2019)

Impact of anti-VEGF therapy on distinctive retina layers in patients with macular edema secondary to branch retinal vein occlusion
por: Wang, Hui, et al.
Publicado: (2023)

Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity
por: Yu, Ying, et al.
Publicado: (2020)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy
por: Rossino, Maria Grazia, et al.
Publicado: (2020)

Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)
por: Rojo Arias, Jesús Eduardo, et al.
Publicado: (2021)

The role of external eyelid weights in acute facial palsy: functional and aesthetic considerations
por: Sri Shanmuganathan, Vishnu, et al.
Publicado: (2018)

Laryngotracheal stenosis following intubation and tracheostomy for COVID-19 pneumonia: a case report
por: Vasanthan, Rishi, et al.
Publicado: (2021)

Vegf signaling between Müller glia and vascular endothelial cells is regulated by immune cells and stimulates retina regeneration
por: Mitra, Soumitra, et al.
Publicado: (2022)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application
por: Zhang, Yan, et al.
Publicado: (2015)

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination
por: Courtaut, Flavie, et al.
Publicado: (2021)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
por: Bahr, Tyler A., et al.
Publicado: (2023)

Nanoparticles as a tool to deliver drugs to the retina and brain: an update
por: You, Qing, et al.
Publicado: (2020)

Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells
por: Sghaier, Randa, et al.
Publicado: (2022)

Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina
por: Balser, Carsten, et al.
Publicado: (2019)

The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells
por: Chan, Chi-Ming, et al.
Publicado: (2019)

Responding to the Pandemic: An Update From the GSA COVID-19 Task Force
por: Hyer, Kathryn, et al.
Publicado: (2020)

CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
por: Ma, Shaolin, et al.
Publicado: (2021)

The role of Anti-VEGF agents in treatment of neovascular glaucoma
por: Palfi (Salavat), Mădălina-Casiana, et al.
Publicado: (2022)

Hyperactivation of retina by light in mice leads to photoreceptor cell death mediated by VEGF and retinal pigment epithelium permeability
por: Cachafeiro, M, et al.
Publicado: (2013)

Using QR smartphone technology to improve patient communication and information distribution
por: Azad, Afshaun, et al.
Publicado: (2021)

Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)

Anti-VEGF drugs in the prevention of blindness
por: Yorston, David
Publicado: (2014)

Anti-VEGF drugs: evidence for effectiveness
por: Evans, Jennifer, et al.
Publicado: (2014)

Tumor refractoriness to anti-VEGF therapy
por: Ribatti, Domenico
Publicado: (2016)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Tuberculosis pathophysiology and anti-VEGF intervention
por: Maison, David P.
Publicado: (2022)

Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpmsva0p61g1rijcbsgo4gjr1d